2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 500

The Dysregulation of NK Cells and Non-Conventional NK-T and γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis
Abstract Number: 868

The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud Phenomenon in Early Diffuse Scleroderma: Results of the “Tamer”‘ Study
Abstract Number: 2400

The Effect of Co-medication with Methotrexate and Other Conventional Synthetic Disease Modifying Anti-rheumatic Drugs on First Tumor Necrosis Inhibitor Drug Survival in Patients with Rheumatoid Arthritis: Results Form a Nationwide Registry
Abstract Number: 2367

The Effect of DMARDs on Cardiovascular Outcomes in Rheumatoid Arthritis: A Systematic Literature Review
Abstract Number: 13

The Effect of Estrogen and Interferon γ on the Immunobiology of Minor Salivary Gland Mesenchymal Stromal Cells
Abstract Number: 1424

The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial
Abstract Number: 1046

The Effect of Nintedanib versus Mycopheolate Mofetil in the FRA2 Mouse Model of Systemic Sclerosis Associated Interstitial Lung Disease
Abstract Number: 2890

The Effect of Rheumatoid Arthritis and Biologics on the Acquisition of Subsequent Diseases and Adverse Events: A Matched Longitudinal Population Study
Abstract Number: 1502

The Effect of Tofacitinib on Residual Pain in Patients with Psoriatic Arthritis
Abstract Number: 2392

The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis
Abstract Number: 242

The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences
Abstract Number: 902

The Effects of a Low-Fat, Mediterranean, or Low-Carbohydrate Diet on Serum Urate
Abstract Number: 1615

The Effects of Anti-glutamate Receptor Subunit Antiantibodies on Systemic Lupus Erythematosus Without Neuropsychiatric Involvement
Abstract Number: 1538

The Effects of Apremilast Therapy on Deployability in Active Duty U.S. Army Soldiers with Plaque Psoriasis and Psoriatic Arthritis
Abstract Number: 459

The Effects of Erythrocytes and Platelets on Disease Activity in Patients with RA – ANSWER Longitudinal Cohort Study –

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].